TAILIEUCHUNG - The Economic Argument for Disease Prevention: Distinguishing Between Value and Savings

Unsustainable growth in medical spending has sparked interest in the question of whether prevention saves money and could be the answer to the health care crisis. But the question misses the point. What should matter (for both prevention and treatment services) is value -- the health benefit per dollar invested. We discuss a package of effective clinical preventive services that improves health at a relatively low cost. Cost-effectiveness should also be examined for disease care, the major driver of health spending. Health care spending can best be controlled by shifting investments from expensive low-value services to more cost-effective interventions. . | The Economic Argument for Disease Prevention Distinguishing Between Value and Savings A Prevention Policy Paper Commissioned by Partnership for Prevention Steven H. Woolf MD MPH Professor of Family Medicine Virginia Commonwealth University Corinne G. Husten MD MPH Interim President Partnership for Prevention Lawrence S. Lewin MBA Executive Consultant James S. Marks MD MPH Senior Vice President Robert Wood Johnson Foundation Jonathan E. Fielding MD MPH MBA Director of Public Health and Health Officer Los Angeles County Department of Public Health Professor of Health Services and Pediatrics UCLA Schools of Public Health and Medicine Eduardo J. Sanchez MD MPH Vice President and Chief Medical Officer Blue Cross and Blue Shield of Texas Partnership for Prevention Shaping Policies Improving Health The Economic Argument for Disease Prevention Distinguishing Between Value and Savings Executive Summary Unsustainable growth in medical spending has sparked interest in the question of whether prevention saves money and could be the answer to the health care crisis. But the question misses the point. What should matter for both prevention and treatment services is value -- the health benefit per dollar invested. We discuss a package of effective clinical preventive services that improves health at a relatively low cost. Cost-effectiveness should also be examined for disease care the major driver of health spending. Health care spending can best be controlled by shifting investments from expensive low-value services to more cost-effective interventions. Note The authors prepared this paper on behalf of the National Commission on Prevention Priorities NCPP which is convened by Partnership for Prevention. The NCPP guides Partnership for Prevention s work to assess the value of prevention. Partnership for Prevention and the NCPP gratefully acknowledge support from WellPoint Foundation Robert Wood Johnson Foundation and Centers for Disease Control and Prevention. February 2009 2 The

• Y học thường thức
• Therapeutic Advances
• Stereotactic Radiosurgery
• Surgical Treatment
• Streptococcal Toxin
• Streptolysin S
• Anesthesia
• Therapeutic proteins
• Protein classification
• Production of therapeutic proteins
• Pharmacokinetics of therapeutic proteins
• Protein stability
• Protein degradation
• Ghazala Hayat
• Peripheral
• Neuropathy
• Diagnostic
• Therapeutic
• Health
• Recombinant therapeutic protein
• Transient gene expression
• Different expression systems
• Recent advances
• Transient gene expression protocol
• Cell lines used
• Eloquent Areas
• Modified Boron Neutron
• Diagnosed Glioblastoma
• Elderly Women
• Urinary Incontinence
• Long Term Care
• Geriatric Urinary
• Incontinence – Special
• Frail Elderly
• Oxidative Stress
• Diagnosis and Treatment
• Current Insights
• Future Advances
• Endometriosis Diagnostics
• Imaging Tools
• Emerging Impact
• Gastroenterology
• Intestinal Microbial
• Flora – Effect
• Probiotics in Newborns
• Benefits and Challenges